Business
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease Baseline Demographics Presented at ARVO Annual Meeting with Summary Audio and Slide Presentation Available on Opus Website Three-Month Topline Results from Cohort 1 Expected in September 2026 RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene
About this update from Opus Genetics, Inc.
[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1cXWyemNkrNdnQ8pvyVh0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MQ--/https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0","width":300,"height":129},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/1cXWyemNkrNdnQ8pvyVh0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MQ--/https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0","width":300,"height":129}},"lazy":false},{"type":"text","content":"Target Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease","length":116,"tagName":"p"},{"type":"text","content":"Baseline Demographics Presented at ARVO Annual Meeting with Summary Audio and Slide Presentation Available on Opus Website ","length":122,"tagName":"p"},{"type":"text","content":"Three-Month Topline Results from Cohort 1 Expected in September 2026","length":68,"tagName":"p"},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the completion of enrollment in Cohort 1 of its ongoing Phase 1/2 study of OPGx-BEST1 gene therapy.","length":409,"tagName":"p"},{"type":"text","content":"The adaptive, open-label study is evaluating the safety and efficacy of single-eye subretinal administration of OPGx-BEST1 up to two dose levels in adult participants with Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB). Five participants have been enrolled in the study, three with BVMD and two with ARB. The first four participants have been dosed and the fifth participant is scheduled for the dosing procedure this month.","length":465,"tagName":"p"},{"type":"text","content":"“As planned, we enrolled a mix of participants with the dominant and recessive forms of BEST disease to evaluate OPGx-BEST1 in both conditions,” said George Magrat...